They say that history is written by the victors. Not always. Sometimes histories are written by advocates for the oppressed and disenfranchised. A common theme on our website is the need to see current practices and thyroid therapy challenges in… Read More ›
A trend in thyroid therapy, sparked by a 1995 rat study, attempted to mimic a narrowly estimated T3:T4 ratio secreted by human thyroid glands. This trend was based on a theory of pharmaceutical mimicry of “the” thyroid gland. Its proponents… Read More ›
Lack of knowledge about Free T3 peaks and valleys contributes to failure and frustration in T3-based therapies, including desiccated thyroid and T3-T4 combination therapy. On patient support groups, I often see conversations that go like this: “My FT3 result was… Read More ›
Sigh. Just sigh. Even some of our best thyroid patient advocates can unknowingly share misinformation about thyroid therapy. Mary Shomon’s thyroid articles on Verywell.com are usually to be trusted. But yesterday I was saddened to see that an article supposedly… Read More ›
What does NEW thyroid science have to say on the topic of thyroid pharmaceutical equivalency? How many micrograms of L-T3 Liothyronine (i.e. Cytomel) are equivalent to L-T4 Levothyroxine (i.e. Synthroid)? Thyroid hormone pharmaceutical monographs currently provide very rigid and low-ratio… Read More ›
In thyroid therapy, how many micrograms of Cytomel (T3) are equivalent to how many micrograms of Synthroid (T4)? Pharmaceutical equivalency statements in the product monographs for Pfizer Canada’s Cytomel and for ERFA Canada’s “Thyroid” (desiccated thyroid extract, DTE, or natural… Read More ›
Here I bring thyroid science into a discussion of effectively adapting and managing the most flexible form of thyroid therapy, T4-T3 combination therapy. This is a model capable of adapting to an individual’s unique thyroid disability and response to thyroid… Read More ›
I’d like to talk about contemporary researchers’ rigid and limited approach to combination therapy. This is the model whose many limitations I point out with the ridiculously long label “mini-T3-mono-combination” therapy. I’ll go over some of the history behind this… Read More ›